Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation

American Journal of Cardiology

Volumn 80, Issue 3 A, 1997, Pages 132A-136A

  Minshall, Richard D ^a   Erdös, Ervin G ^a   Vogel, Stephen M ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXY 5 QUINOLINESULFONIC ACID; BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ[3 HYDROXYPROLINE 8 TYROSYLMETHIONINE]; DEXTRAN BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ICATIBANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; GUINEA PIG; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TACHYPHYLAXIS;

EID: 0030762787     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00468-2     Document Type: Conference Paper

References (37)

1. Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation. 58:1978;770-776.
2. Gavras I, Gavras H. ACE inhibitors: a decade of clinical experience. Hosp Pract. 15:1993;61-71.
3. Pfeffer MA. Angiotensin-converting enzyme inhibition in congestive heart failure: benefit and perspective. Am Heart J. 126:1993;789-793.
4. Pfeffer MA. ACE inhibition in acute myocardial infarction. N Engl J Med. 332:1995;118-120.
5. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47:1995;25-49.
6. Yang HYT, Erdös EG. Second kininase in human blood plasma. Nature. 215:1967;1402-1403.
7. Yang HYT, Erdös EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta. 214:1970;374-376.
8. Yang HYT, Erdös EG, Levin Y. Characterization of a dipeptide hydrolase (kininase II; angiotensin I converting enzyme). J Pharmacol Exp Ther. 177:1971;291-300.
9. Skidgel RA, Erdös EG. Biochemistry of angiotensin converting enzyme. Robertson JIS, Nicholls MG. The Renin-Angiotensin System. 1:1993;10.1-10.10 Gower Medical Publishing, London.
10. Carretero OA, Scicli AG. The kallikrein-kinin system as a regulator of cardiovascular and renal function. Laragh JH, Brenner BM. Hypertension: Pathophysiology, Diagnosis, and Management. 1995;983-999 Raven Press, New York.
11. Erdös EG, Yang HYT. Kininases. (Handbook of Experimental Pharmacology). XXV:1970;289-323 Springer-Verlag, Heidelberg.
12. Erdös EG, Skidgel RA. Metabolism of bradykinin by peptidases in health and disease. Farmer SG. The Kinin System (Handbook of Immunopharmacology). 1997;111-141 Academic Press, London.
13. Auch-Schwelk W, Bossaller C, Claus M, Graf K, Gräfe M, Fleck E. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res. 27:1993;312-317.
14. Montague E, Rosas R, Bohr DF. Bradykinin: vascular relaxant, cardiac stimulant. Science. 141:1963;907-908.
15. Heeg E, Meng K. Die Wirkung des Bradykinins, Angiotensins und Vasopressins auf Vorhof, Papillarmuskel und isoliert durchströmte Herzpräparate des Meerschweinchens. Naunyn Schmiedebergs Arch Pharmacol. 250:1965;35-41.
16. Tio RA, Scholtens E, van Gilst WH, de Langen CDJ, Wesseling H. The effects of bradykinin and bradykinin antagonists on the isolated rat heart. Pharmacol Commun. 1:1992;185-192.
17. Munch PA, Longhurst JC. Bradykinin increases myocardial contractility: relation to the Gregg phenomenon. Am J Physiol. 260:1991;R1095-R1103.
18. Iven H, Pursche R, Zetler G. Field stimulus response of guinea pig atria as influenced by the peptides angiotensin, bradykinin, and substance P. Naunyn Schmiedebergs Arch Pharmacol. 312:1980;63-68.
19. Minshall RD, Yelamanchi VP, Djokovic A, Miletich DJ, Erdös EG, Rabito SF, Vogel SM. Importance of the sympathetic innervation in the positive inotropic effects of bradykinin and ramiprilat. Circ Res. 74:1994;441-447.
20. Minshall RD, Nakamura F, Becker RP, Rabito SF. Characterization of bradykinin B2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res. 76:1995;773-780.
21. Minshall RD, Vogel SM, Miletich DJ, Erdös EG. Potentiation of the inotropic actions of bradykinin on the isolated guinea pig left atria by the angiotensin I converting enzyme/kininase II inhibitor, enalaprilat. Circulation. 92:((suppl)):1995;1-221.
22. Chulak C, Coulture R, Foulart S. Modulatory effect of bradykinin on release of noradrenaline from isolated atria. Br J Pharmacol. 115:1995;330-334.
23. Manning DC, Vavrek R, Stewart JM, Snyder SH. Two bradykinin binding sites with picomolar affinities. J Pharmacol Exp Ther. 237:1986;504-512.
24. Revytak GE, Buja LM, Chien KR, Campbell WB. Reduced arachidonate metabolism in ATP-depleted myocardial cells occurs early in cell injury. Am J Physiol. 258:1990;H582-H591.
25. Chi C-W, Wang S-Z, Xu L-G, Wang M-Y, Lo S-S, Huang W-D. Structure-function studies on the bradykinin potentiating peptide from Chinese snake venom (Agkistrodon halys Pallas). Peptides. 6:((suppl 3)):1985;339-342.
26. Hecker M, Pörsti K, Bara AT, Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol. 111:1994;238-244.
27. Erdös EG, Wohler JR. Inhibition in vivo of the enzymatic inactivation of bradykinin and kallidin. Biochem Pharmacol. 12:1963;1193-1199.
28. Odya CE, Levin Y, Erdös EG, Robinson CJG. Soluble dextran complexes of kallikrein, bradykinin and enzyme inhibitors. Biochem Pharmacol. 27:1978;173-179.
29. Dragovic T, Minshall R, Jackman HL, Wang L-X, Erdös EG. Kininase II-type enzymes, their putative role in muscle energy metabolism. Diabetes. 45:1996;S34-S37.
30. 3H]-bradykinin dissociates slowly. J Biol Chem. 265:1990;9621-9627.
31. 2 kinin receptor in the presence and absence of guanine nucleotides. Biochem J. 276:1991;141-147.
32. Sibley DR, Lefkowitz RJ. Molecular mechanisms of receptor desensitization using the β -adrenergic receptor-coupled adenylate cyclase system as a model. Nature. 317:1985;124-129.
33. Benovic JL, Mayor F, Somers RL, Caron MG, Lefkowitz RJ. Light-dependent phosphorylation of rhodopsin by β -adrenergic receptor kinase. Nature. 321:1986;869-872.
34. Kwatra MM, Hosey MM. Phosphorylation of the cardiac muscarinic receptor in intact chick heart and its regulation by a muscarinic agonist. J Biol Chem. 261:1986;12429-12432.
35. Roberts RA, Gullick WJ. Bradykinin receptors undergo ligand-induced desensitization. Biochemistry. 29:1990;1975-1979.
36. 2 -adrenergic receptors by protein kinase C and cyclic AMP dependent protein kinase. J Biol Chem. 262:1987;3106-3113.
37. 1B -adrenergic receptor subcellular distribution and function. J Biol Chem. 270:1995;8902-8909.